Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
No Surprises from Vertex (VRTX) But Piper Jaffray Moves Price Target Down to $143
January 28, 2016 7:25 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating but lowered his price target on Vertex (NASDAQ: VRTX) to $143.00 (from $180.00) following results which offered no surprises.
Tenthoff commented, "As pre-announced, >4,500 patients began ORKAMBI in the U.S. resulting in sales of $220 million in 4Q:15;... More
Vertex Pharma (VRTX) Reports In-Line Q4 EPS
January 27, 2016 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.17, in-line with the analyst estimate of $0.17. Revenue for the quarter came in at $417.94 million versus the consensus estimate of $406.3 million.
"Entering 2016, Vertex is in a strong financial position to support continued investment in our business to create future medicines for serious diseases and value for our shareholders," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "We look forward... More
